Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Company

10/14/2021 | 01:02am EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
11:49aGLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
04:28aMerck Prices $8 Billion Senior Notes Offering
MT
04:17aLytix Biopharma Starts Treatment of First Patient in Mid-Stage Trial for Tumor Drug
MT
12/07Merck & Co. Allocates Additional $150 Million For Global Maternal Health Program
MT
12/07Merck Prices $8.0 Billion Debt Offering
BU
12/07Merck Announces Five-Part US Dollar Issuance With Maturities From 5-40 Years
MT
12/07Guggenheim Downgrades Merck to Neutral From Buy
MT
12/07Merck Pledges Additional $150 Million to End Maternal Mortality Inequities
MT
12/07Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality..
BU
12/07NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 ..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 576 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 14,9x
Yield 2021 3,59%
Capitalization 183 B 183 B -
EV / Sales 2021 4,18x
EV / Sales 2022 3,50x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 72,28 $
Average target price 95,11 $
Spread / Average Target 31,6%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-11.64%182 575
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215